Odesivimab

Odesivimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Zaire ebolavirus glycoprotein
Clinical data
Pronunciation	oh" de siv' i mab
License data	US DailyMed: Odesivimab ;
Drug class	Monoclonal antibody
ATC code	None;
Identifiers
CAS Number	2135632-30-1 ;
UNII	UY9LQ8P6HW ;
KEGG	D11921 ;
Chemical and physical data
Formula	C6506H10024N1720O2030S42
Molar mass	146164.29 g·mol−1

Last updated July 17, 2025

Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).^[1]^[2]

References

↑ "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Archived from the original on 15 October 2020. Retrieved 14 October 2020. This article incorporates text from this source, which is in the public domain .
↑ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

External links

"Odesivimab". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 29 August 2021.
"Statement on a nonproprietary name adopted by the USAN Council USAN (FG-102) Odesivimab" (PDF).

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[FDA_PR-1] "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Archived from the original on 15 October 2020. Retrieved 14 October 2020. This article incorporates text from this source, which is in the public domain .

[2] "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

[1]

[2]